Bone health management in patients with prostate cancer

This guidance provides clear recommendations to help clinicians prevent and manage therapy induced osteoporotic fragility fractures and skeletal related events in patients undergoing prostate cancer treatment. It has been developed by a multidisciplinary group of experts, including oncologists, urologists, metabolic bone specialists, dentists, pharmacists, rheumatologists, orthogeriatricians, specialist nurses and a patient representative, ensuring a comprehensive and practical clinical resource.

We are proud to share that the guidance has been endorsed by the British Uro Oncology Group, The British Association of Urological Surgeons, The British Association of Urological Nurses, Prostate Cancer UK, The Royal Osteoporosis Society and Prostate Cancer Research.